Trial Profile
A Phase 1b, Open-Label Study to Evaluate the Safety of AMG 479 in Combination with Gemcitabine as First-line Therapy for Metastatic Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 May 2016
Price :
$35
*
At a glance
- Drugs Ganitumab (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Takeda Bio Development Center
- 03 Nov 2015 New trial record